WO2020203753A1 - Procédé de préparation d'une population cellulaire comprenant des cellules précurseurs du foie - Google Patents

Procédé de préparation d'une population cellulaire comprenant des cellules précurseurs du foie Download PDF

Info

Publication number
WO2020203753A1
WO2020203753A1 PCT/JP2020/013987 JP2020013987W WO2020203753A1 WO 2020203753 A1 WO2020203753 A1 WO 2020203753A1 JP 2020013987 W JP2020013987 W JP 2020013987W WO 2020203753 A1 WO2020203753 A1 WO 2020203753A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell population
cell
fibroblasts
hepatic progenitor
Prior art date
Application number
PCT/JP2020/013987
Other languages
English (en)
Japanese (ja)
Inventor
裕輔 堺
晋 江口
Original Assignee
国立大学法人 長崎大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 長崎大学 filed Critical 国立大学法人 長崎大学
Priority to US17/599,619 priority Critical patent/US20220160785A1/en
Publication of WO2020203753A1 publication Critical patent/WO2020203753A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/28—Materials or treatment for tissue regeneration for liver reconstruction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Definitions

  • the present invention relates to a method for producing a cell population containing hepatic progenitor cells and the like, which comprises a step of removing fibroblasts from a cell population containing hepatic progenitor cells and fibroblasts.
  • hepatic progenitor cells are attracting attention as a cell source, but hepatic progenitor cells are present only in a small amount in the liver, and it is difficult to collect them.
  • hepatocytes / progenitor cells can be produced by contacting mammalian hepatocytes with a TGF ⁇ receptor inhibitor, a GSK3 inhibitor and / or a ROCK inhibitor (Patent Document 1 and non-patent documents 1).
  • Patent Document 1 Patent Document 1 and non-patent documents 1).
  • human hepatocyte progenitor cells can be prepared by culturing mature human hepatocytes in a medium containing serum, A-83-01 (TGF ⁇ signal inhibitor) and CHIR99021 (GSK3 inhibitor) (Patent Document). 2).
  • the liver contains hepatocytes and fibroblasts, it was obtained from hepatocytes by a cell population containing hepatic precursor cells isolated from the liver or by a reprogramming method using a low molecular weight compound by the above method.
  • Fibroblasts are mixed in the cell population including hepatic precursor cells. Since fibroblasts proliferate faster than hepatic progenitor cells, the presence of fibroblasts in the culture hinders the proliferation of hepatic progenitor cells. Therefore, when using a cell population containing hepatic progenitor cells, it is necessary to remove fibroblasts in advance to increase the purity of hepatic progenitor cells.
  • the FACS (Fluorescence activated cell sorting) method and the MACS (Magnetic cell sorting) method are generally used.
  • FACS Fluorescence activated cell sorting
  • MACS Magnetic cell sorting
  • An object of the present invention is to provide a method for producing a cell population in which fibroblasts are sufficiently removed from a cell population containing hepatic progenitor cells and fibroblasts without using FACS or MACS. To do. Another problem with this method is that the purity of hepatic progenitor cells can be stably maintained at a high rate for a long period of time even after repeated passages. Furthermore, it is also an object to provide a cell population with high purity of hepatic progenitor cells by using such a method.
  • the present inventors focused on the difference in adhesion between hepatic progenitor cells and fibroblasts to the culture medium, and used one or more different types of culture medium to obtain the above. I got the idea that hepatic progenitor cells and fibroblasts could be separated by adhesiveness. As a result of conducting research based on this idea, it was found that fibroblasts can be sufficiently removed from a cell population containing hepatic progenitor cells and fibroblasts, and the present invention has been completed.
  • the present invention is as follows.
  • [1] A method for producing a cell population containing hepatic progenitor cells. (1) Step of preparing a culture substrate containing a hepatic progenitor cell and a cell population containing fibroblasts, (2) A step of physically removing a colony of fibroblasts from the culture medium, (3) A step of detaching cells from the culture substrate and collecting the detached cells, and (4) A method comprising a step of culturing the cells recovered in the step (3) on a collagen-coated culture substrate and recovering the cells not adhered to the culture substrate.
  • step (5) further includes a step of culturing the recovered cells on a collagen-coated culture medium and removing cells that have not adhered to the culture medium [1]. ]
  • the method described in. [3] During step (3) and step (4), (3') the recovered cells are cultured on a gelatin-coated culture medium, and cells not adhered to the culture medium are recovered.
  • step (5) further comprises (6) the step of exfoliating and recovering the cells adhering to the culture substrate from the culture substrate before reaching confluence [2] or [3].
  • step (7) further includes a step of exfoliating and recovering the cells adhered to the culture substrate from the culture substrate after reaching confluence [2] or [3].
  • the method described in. [6] The method according to any one of [1] to [5], wherein the culture time in step (4) is 5 to 15 minutes.
  • the cell population prepared in step (1) is a cell population containing hepatic progenitor cells obtained by reprogramming hepatocytes.
  • step 8 The method according to any one of [3] to [7], wherein the steps (3') to (5) are repeated at least twice.
  • a method of removing fibroblasts from a cell population containing hepatic progenitor cells and fibroblasts (1) Step of preparing a culture substrate containing a hepatic progenitor cell and a cell population containing fibroblasts, (2) A step of physically removing a colony of fibroblasts from the culture medium, (3) A step of detaching cells from the culture substrate and collecting the detached cells, and (4) A method comprising a step of culturing the cells recovered in the step (3) on a collagen-coated culture substrate and recovering the cells not adhered to the culture substrate.
  • a cell population containing hepatic progenitor cells obtained by any of the methods [1] to [8].
  • a cell transplant therapy agent comprising the cell population according to [10].
  • a cell population containing hepatocytes which is obtained by inducing differentiation of the cell population described in [10].
  • a cell population containing bile duct epithelial cells obtained by inducing differentiation of the cell population described in [10].
  • a method for assessing the metabolism of test compounds in mammals (1) The step of contacting the cell according to any one of [10], [12] and [13] with the test compound, and (2) A method comprising the step of measuring the metabolism of a test compound in the cells.
  • a method for assessing hepatotoxicity of test compounds to mammals are examples of test compounds to mammals.
  • a method for producing a cell population in which fibroblasts are sufficiently removed from a cell population containing hepatocyte-derived hepatic progenitor cells and fibroblasts without using FACS or MACS is provided.
  • the purity of hepatic progenitor cells can be stably maintained at a high rate for a long period of time even after repeated passages.
  • such methods are used to provide a highly pure cell population of hepatic progenitor cells. Since the hepatic progenitor cells obtained in the present invention do not use FACS or MACS, they can have higher activity than the hepatic progenitor cells obtained by the conventional method using them.
  • FIG. 1 is a diagram showing an outline of the present invention.
  • the upper row is an example of a method related to the step of physically removing a colony of fibroblasts from a cell substrate.
  • FIG. 2 is a phase-contrast microscopic image of cells obtained by culturing a cell population containing hepatic progenitor cells and fibroblasts on a gelatin-coated and collagen-coated culture medium. From the left, cells were cultured on a gelatin-coated culture medium, a collagen-coated culture medium, and a collagen-coated culture medium, respectively.
  • FIG. 1 is a diagram showing an outline of the present invention.
  • the upper row is an example of a method related to the step of physically removing a colony of fibroblasts from a cell substrate.
  • FIG. 2 is a phase-contrast microscopic image of cells obtained by culturing a cell population containing hepatic progenitor cells and fibroblasts on a gelatin-
  • FIG. 3 is a phase-contrast microscopic image of cells obtained by culturing a cell population containing hepatic progenitor cells and fibroblasts on a gelatin-coated and collagen-coated culture medium, as in FIG. From the left, cells were cultured on a gelatin-coated culture medium, a collagen-coated culture medium, and a collagen-coated culture medium, respectively.
  • the present invention provides a method for producing a cell population containing hepatic progenitor cells (hereinafter, may be referred to as "the production method of the present invention").
  • the production method of the present invention is as follows: (1) Step of preparing a culture substrate containing a hepatic progenitor cell and a cell population containing fibroblasts, (2) A step of physically removing a colony of fibroblasts from the culture medium, (3) A step of detaching cells from the culture substrate and collecting the detached cells, and (4) The step of culturing the cells recovered in the step (3) on a collagen-coated culture substrate and recovering the cells not adhered to the culture substrate is included.
  • the present invention also includes a method for removing fibroblasts from a cell population containing hepatic progenitor cells and fibroblasts, which comprises the above steps (1) to (4) (hereinafter, "method for removing the present invention”). May be referred to as).
  • method for removing the present invention comprises the above steps (1) to (4)
  • the production method of the present invention and the removal method of the present invention may be collectively referred to as "the method of the present invention”.
  • the hepatic progenitor cells contained in the cell population prepared in the step (1) are not particularly limited, and may be, for example, hepatic progenitor cells isolated from the liver using FACS, MACS, or the like, or hepatic cells. Can be a hepatic progenitor cell established by reprogramming using a low molecular weight compound, but from the viewpoint that a sufficient amount of cells can be obtained, the liver established by reprogramming the hepatic cell.
  • Progenitor cells hereinafter, may be referred to as "CLiP (Chemically-induced Liver Progenitor)" are preferable.
  • the method for isolating hepatic progenitor cells from the liver can be carried out by a method known per se, and examples thereof include a method for isolating using FACS or MACS using the markers of hepatic progenitor cells described below as an index. Be done.
  • the hepatocyte reprogramming method can also be performed by the method known per se as described below.
  • hepatic progenitor cells and fibroblasts are usually mixed in the cell population containing the hepatic progenitor cells thus obtained.
  • the culture substrate containing the cell population is not particularly limited, and for example, a dish, a Petri dish, a tissue culture dish, a multi-dish, a microplate, a microwell plate, a multi-plate, a multi-well plate, a chamber slide, etc. Petri dishes and the like.
  • hepatic progenitor cell means a cell having (a) self-renewal ability and (b) an ambiguous cell capable of differentiating into both hepatocytes and bile duct epithelial cells.
  • bile duct epithelial cells also referred to as “BEC” refer to cells expressing the BEC markers cytokeratin 19 (CK19) and GRHL2.
  • Hepatic progenitor cells also include fetal liver hepatic blast cells and oval cells that appear during liver injury.
  • the hepatic progenitor cells used in the method of the present invention express (c) an epithelial cell adhesion molecule (EpCAM) as a surface antigen marker in addition to the properties (a) and (b) above. Also, in one embodiment, the hepatic progenitor cells used in the method of the invention do not express the known LSC markers delta homolog 1 (Dlk1), leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) and FoxL1. ..
  • EpCAM epithelial cell adhesion molecule
  • CLiP is, for example, a method comprising contacting mammalian hepatocytes with a TGF ⁇ receptor inhibitor in vitro (WO2017 / 119512 A1, CellStem Cell 20, 41-55, January 5, 2017) (hereinafter, It can be prepared by (sometimes referred to as "method for producing hepatocytes / progenitor cells”).
  • CLiP is a method including culturing human mature hepatocytes in a medium containing serum, A-83-01 and CHIR99021 (WO 2018/079714 A1) (hereinafter, "method for preparing human hepatic progenitor cells”). It can also be produced by (may be referred to as).
  • cell population in the present invention a step of preparing a cell population containing hepatocyte-derived hepatic progenitor cells and fibroblasts (hereinafter, may be referred to as “cell population in the present invention”) will be described based on the method for producing CLiP.
  • hepatocytes used as a starting material for the cell population in the present invention are hepatocyte marker genes (eg, albumin (ALB), transcyletin (TTR), glucose-6-phosphatase (G6PC), tyrosine aminotransferase (eg, albumin (ALB), transcyretin (TTR), glucose-6-phosphatase (G6PC)) TAT), tryptophan-2,3-dioxygenase (TDO2), cytochrome P450 (CYP), miR-122, etc.) at least one (preferably two or more selected from ALB, TTR, G6PC, TAT, TDO2 and CYP) , More preferably 3 or more, still more preferably 4 or more, particularly preferably 5 or more, most preferably all 6).
  • hepatocyte marker genes eg, albumin (ALB), transcyletin (TTR), glucose-6-phosphatase (G6PC), tyrosine aminotransferase (e
  • hepatocytes are (i) have a bile canaliculus structure and accumulate drug metabolites in the canaliculus, (ii) express ABC transporters (eg, MDR1, MRP, etc.) on the cell membrane. (iii) ALB secretion expression, (iv) glycogen accumulation, (v) drug-metabolizing enzyme (eg, CYP1A1, CYP1A2, etc.) activity selected from 1 or more, preferably 2 or more, more preferably 3 or more, still more preferably 4 The above is most preferably a hepatocyte that retains all functions.
  • ABC transporters eg, MDR1, MRP, etc.
  • the hepatocytes used to prepare the cell population in the present invention may be provided from any source as long as they are characterized by the expression of the hepatocyte marker gene, for example, mammals (eg, humans, rats, mice).
  • mammals eg, humans, rats, mice.
  • a method known per se from pluripotent stem cells such as embryonic stem cells (ES cells) of guinea pigs, rabbits, sheep, horses, pigs, cows, monkeys, preferably humans, rats, mice) or iPS cells (
  • ES cells embryonic stem cells
  • hepatocytes obtained by Zhu, S. et al., Nature 508, 93-97 (2014) or hepatocytes derived from fibroblasts by direct reprogramming (Huang, P. et al.).
  • hepatocytes isolated and purified from the liver extracted from mammals as hepatocytes.
  • mammals For example, in the case of rats, it is preferable to use a liver extracted from an adult rat 10 to 20 weeks old, but a liver derived from an immature rat 2 months or younger may be used.
  • a liver excised from a dead fetus may be used.
  • a non-cancerous tissue of the liver tissue resected due to liver cancer or the like may be used.
  • frozen cells (frozen hepatocytes) of hepatocytes isolated and purified from the excised liver or non-cancerous tissue of the liver tissue can also be used.
  • Examples of a method for purifying hepatocytes from a mammalian liver or a tissue fragment thereof include a perfusion method (“Cultivated Cell Experiment Handbook” (Yodosha, 2004), etc.). That is, after pre-perfusion with EGTA solution through the portal vein, perfusion with an enzyme solution (Hanks solution, etc.) such as collagenase or dispase is performed to digest the liver, and cell debris and non-parenchymal cells are removed by filtration, slow centrifugation, etc. Purify hepatocytes.
  • a perfusion method (“Cultivated Cell Experiment Handbook” (Yodosha, 2004), etc.). That is, after pre-perfusion with EGTA solution through the portal vein, perfusion with an enzyme solution (Hanks solution, etc.) such as collagenase or dispase is performed to digest the liver, and cell debris and non-parenchymal cells are removed by filtration, slow centrifugation, etc. Purify hepatocytes.
  • TGF ⁇ receptor inhibitors include TGF ⁇ receptor inhibitors.
  • the TGF ⁇ receptor inhibitor used for the preparation of the cell population in the present invention is not particularly limited as long as it has an action of inhibiting the function of the transforming growth factor (TGF) ⁇ receptor, and is not particularly limited.
  • TGF ⁇ receptor inhibitors also include TGF ⁇ receptor antagonists. As these TGF ⁇ receptor inhibitors,
  • low-molecular-weight signal transduction pathway inhibitors other than TGF ⁇ receptor inhibitors include GSK3 inhibitors and ROCK inhibitors.
  • the GSK3 inhibitor used for the preparation of the cell population in the present invention is not particularly limited as long as it has an action of inhibiting the function of glycogen synthase kinase (GSK) 3, for example, SB216763 (Selleck). ), CHIR98014 (Axon medchem), CHIR99021 (Axon medchem, AdooQ BioScience), SB415286 (Tocris Bioscience), Kenpaullone (Cosmo Bio), etc. CHIR99021 is preferably mentioned. These GSK3 inhibitors may use one compound or a combination of two or more compounds.
  • GSK3 inhibitors may use one compound or a combination of two or more compounds.
  • ROCK inhibitor used for the preparation of the cell population in the present invention is not particularly limited as long as it has an action of inhibiting the function of Rho-binding kinase.
  • ROCK inhibitors include GSK269962A (Axon medchem), Fasudil hydrochloride (Tocris Bioscience), Y-27632 (Wako Pure Chemical Industries, Ltd., AdooQ BioScience), H-1152 (Wako Pure Chemical Industries, Ltd.). Can be mentioned. Y-27632 is preferably mentioned. These ROCK inhibitors may use one kind of compound or may use two or more kinds of compounds in combination.
  • GSK3 inhibitors and ROCK inhibitors can hardly induce CLiP when they are contacted with hepatocytes alone, but when GSK3 inhibitors are contacted with hepatocytes together with TGF ⁇ receptor inhibitors, TGF ⁇ receptors
  • the induction efficiency of CLiP (also referred to as "reprogramming efficiency") is significantly increased as compared to the case where only the inhibitor is contacted.
  • the reprogramming efficiency is increased as compared with the case where only the TGF ⁇ receptor inhibitor is brought into contact.
  • A-83-01 (A) was used as a TGF ⁇ receptor inhibitor
  • CHIR99021 (C) was used as a GSK3 inhibitor (AC)
  • A-83-01 (A) was used as a TGF ⁇ receptor inhibitor.
  • Combine Y-27632 (Y) as a ROCK inhibitor (YA) use A-83-01 (A) as a TGF ⁇ receptor inhibitor, CHIR99021 (C) as a GSK3 inhibitor, and Y- as a ROCK inhibitor.
  • a combination of 27632 (Y) (YAC) is preferred.
  • TGF ⁇ receptor inhibitors, GSK3 inhibitors and ROCK inhibitors are contacted with hepatocytes.
  • a small molecule signal transduction pathway inhibitor other than the GSK3 inhibitor and the ROCK inhibitor can be combined with the TGF ⁇ receptor inhibitor.
  • examples of such inhibitors include, but are not limited to, MEK inhibitors.
  • the MEK inhibitor is not particularly limited as long as it has an action of inhibiting the function of MEK (MAP kinase-ERK kinase).
  • MEK MAP kinase-ERK kinase
  • AZD6244, CI-1040 (PD184352), PD0325901, RDEA119 BAY869766).
  • SL327, U0126 aboveve, Selleck
  • PD98059 U0124
  • U0125 aboveve, Cosmo Bio
  • contact between hepatocytes and low molecular weight signal transduction pathway inhibitors including TGF ⁇ receptor inhibitors can be achieved by culturing hepatocytes in the presence of these inhibitors. .. Specifically, these inhibitors are added to the medium at an effective concentration and cultured.
  • the medium a medium widely used for culturing animal cells can be used as the basal medium.
  • Commercially available basal medium may be used, and examples thereof include minimum essential medium (MEM), Dalveco modified minimum essential medium (DMEM), RPMI1640 medium, 199 medium, Ham's F12 medium, William's E medium, and the like.
  • DMEM mixed medium of DMEM and Ham's F12 medium
  • additives to the medium include various amino acids (for example, L-glutamine, L-proline, etc.), various inorganic salts (selenate, LVDS 3, etc.), various vitamins (nicotine amide, ascorbic acid derivative, etc.) , Various antibiotics (eg penicillin, streptomycin, etc.), antifungal agents (eg, amphotericin, etc.), buffers (HEPES, etc.), supplements (insulin-transferrin-serine (ITS) -X supplement, etc.), NaOH, etc.
  • various antibiotics eg penicillin, streptomycin, etc.
  • antifungal agents eg, amphotericin, etc.
  • buffers HPES, etc.
  • supplements insulin-transferrin-serine (ITS) -X supplement, etc.), NaOH, etc.
  • FBS serum substitutes
  • factors such as growth factors, cytokines and hormones are usually added. Examples of these factors include epidermal growth factor (EGF), insulin, transferrin, hepatocyte growth factor (HGF), oncostatin M (OsM), hydrocortisone 21-hemicosuccinic acid or a salt thereof, dexamethasone (Dex) and the like. However, it is not limited to them.
  • EGF epidermal growth factor
  • HGF hepatocyte growth factor
  • OsM oncostatin M
  • Dex dexamethasone
  • the concentration of the TGF ⁇ receptor inhibitor added to the medium is, for example, 0.01 to 10 ⁇ M, preferably 0.1 to 9 ⁇ M, more preferably 0.3 to 7 ⁇ M, and even more preferably 0.5 to 5 ⁇ M.
  • the concentration of the GSK3 inhibitor added to the medium is, for example, 0.01 to 100 ⁇ M, preferably 1 to 10 ⁇ M, more preferably 1 to 5 ⁇ M, and even more preferably 3 ⁇ M.
  • the concentration of the ROCK inhibitor added to the medium is, for example, 0.0001 to 500 ⁇ M, preferably 1 to 50 ⁇ M, more preferably 1 to 25 ⁇ M, and even more preferably 10 ⁇ M.
  • these inhibitors are water-insoluble or poorly water-soluble compounds, they may be dissolved in a small amount of a low-toxic organic solvent (for example, DMSO) and then added to the medium to the above final concentration.
  • the culture vessel used for the culture is not particularly limited as long as it is suitable for adhesive culture, and for example, a dish, a Petri dish, a tissue culture dish, a multi-dish, a microplate, a microwell plate, a multiplate, and a multiwell. Examples include plates, chamber slides, petri dishes, tubes, trays, culture bags and the like.
  • a cell-supporting substrate for the purpose of improving adhesion to cells can be used.
  • cell-supporting substrates include collagen, gelatin, matrigel, poly-L-lysine, laminin, fibronectin and the like. Preferred are collagen or matrigel.
  • Hepatocytes can be seeded on culture vessels at a cell density of 10 2 to 10 6 cells / cm 2 , preferably 10 3 to 10 5 cells / cm 2 (eg, 1.2 x 10 4 cells / cm 2 ). it can. Culturing is carried out in an atmosphere with a CO 2 concentration of 1-10%, preferably 2-5%, more preferably about 5% in a CO 2 incubator, with an oxygen concentration of 1-25%, preferably 2-22%.
  • the culture can be carried out at a temperature of 3 to 20%, a culture temperature of 30 to 40 ° C., preferably 35 to 37.5 ° C., and more preferably about 37 ° C.
  • the culture period includes, for example, 1 to 4 weeks, preferably 1 to 3 weeks, and more preferably about 2 weeks. Alternatively, the period until reaching confluence (for example, 1 to 2 months) can be mentioned. Replace with fresh medium every 1-3 days.
  • hepatocytes can be reprogrammed to CLiP by contacting the hepatocytes with a TGF ⁇ receptor inhibitor and optionally a GSK3 inhibitor and / or a ROCK inhibitor. It is generally believed that mature hepatocytes do not proliferate in vitro, for example, using A-83-01 (A) as a TGF ⁇ receptor inhibitor, CHIR99021 (C) as a GSK3 inhibitor, and as a ROCK inhibitor.
  • A-83-01 (A) as a TGF ⁇ receptor inhibitor
  • CHIR99021 (C) CHIR99021
  • ROCK inhibitor Y-27632
  • rat primary mature hepatocytes seeded at a low density (1 ⁇ 10 2 cells / cm 2 ) were cultured in the presence of YAC, and the proliferation of each single cell was examined by low-velocity imaging.
  • the proportion of single cells that grew to 5 or more cells was about 25%, which was about 1.4% compared to the case of culturing in the absence of YAC. Has increased significantly.
  • Process (2) Examples of the method for physically removing the fibroblast colonies from the culture medium in the step (2) include a method using a scraper, a pipette tip, or the like. Specifically, the position of the fibroblast colony is marked on the culture substrate under a microscope, the fibroblast colony is peeled off using a scraper, a pipette tip, etc., and then washed with a medium to remove the supernatant. There is a way to do it. In order to remove fibroblasts in the subsequent steps, some fibroblast colonies may remain. Further, the step (2) may be performed once or a plurality of times (eg, 2, 3, 4, 5, 6, 7, 8, 9 times) together with the step (3) described later.
  • a plurality of times eg, 2, 3, 4, 5, 6, 7, 8, 9 times
  • Process (3) Examples of the method of exfoliating the cells from the culture substrate in the step (3) and recovering the exfoliated cells include a method of exfoliating and collecting the cells by enzyme treatment or a cell dispersion.
  • the enzyme include trypsin, collagenase, hyaluronidase, elastase, pronase, DNase, papain and the like.
  • the cell dispersion include TrypLE Select (manufactured by Life Technologies) and TrypLE Express (manufactured by Life Technologies).
  • trypsin commercially available trypsin or an alternative thereof (for example, TrypLE TM Express (Thermo Fisher Scientific), etc.) may be used.
  • Contact of cells with trypsin may be carried out under normal culture conditions, for example in an atmosphere of 1-10%, preferably 2-5%, more preferably about 5% CO 2 concentration in a CO 2 incubator. In, 30 to 40 ° C., preferably 35 to 37.5 ° C., more preferably about 37 ° C.
  • the concentration of trypsin is not particularly limited as long as the cell-cell adhesion and the cell-culture substrate adhesion are peeled off, and is, for example, 0.01 to 0.5%, preferably 0.05 to 0.25%.
  • the treatment time is not particularly limited as long as the cell-cell adhesion and the cell-culture substrate adhesion are peeled off, for example, 1 to 15 minutes, preferably 3 to 12 minutes, more preferably 5 to 10 minutes, still more preferably 10. Minutes.
  • the method of collecting the detached cells is not particularly limited, and examples thereof include a method of pipetting the cells with a 5 mL pipette having a large tip diameter and then collecting the supernatant.
  • the collagen-coated culture medium used in step (4) is not particularly limited as long as the surface of the culture medium is coated with collagen.
  • As the collagen-coated culture medium a prepared one may be used, or a commercially available product may be used.
  • For the collagen-coated culture medium for example, after diluting a 0.5% collagen solution sterilized with sterilized 0.01N hydrochloric acid to 0.01%, add the collagen solution to the culture medium, and shake the culture medium to prepare the collagen solution. It can be made by spreading it all over and removing excess collagen solution.
  • Examples of commercially available products include collagen coated dishes (IWAKI) and BioCoa collagen I culture dishes (Corning International Co., Ltd.).
  • the cells recovered in step (3) were collagen-coated with a cell density of, for example, 1 ⁇ 10 4 to 5 ⁇ 10 5 cells / cm 2 , preferably 5 ⁇ 10 4 to 1 ⁇ 10 5 cells / cm 2 . It can be seeded and cultured on a culture substrate.
  • a medium a medium widely used for culturing animal cells can be used as a basal medium.
  • Commercially available basal medium may be used, and examples thereof include minimum essential medium (MEM), Dalveco modified minimum essential medium (DMEM), RPMI1640 medium, 199 medium, Ham's F12 medium, William's E medium, and the like.
  • the culture is carried out, for example, in an atmosphere with a CO 2 concentration of 1-10%, preferably 2-5%, more preferably about 5% in a CO 2 incubator, with an oxygen concentration of 1-25%, preferably 2-22. %, More preferably 3 to 20%, the culture temperature is 30 to 40 ° C, preferably 35 to 37.5 ° C, more preferably about 37 ° C.
  • the culture time is not particularly limited as long as the cells adhere to the culture substrate, and is, for example, 5 to 15 minutes, preferably 7 to 13 minutes, more preferably 8 to 12 minutes, and even more preferably 10 minutes.
  • step (4) in the above short time (5 to 15 minutes), fibroblasts tend to adhere to the culture substrate faster than the hepatic progenitor cells adhere to the collagen-coated culture substrate. Therefore, the purity of hepatic progenitor cells can be increased by collecting unadhered cells after culturing.
  • the cells recovered in the step (4) may be seeded again on the collagen-coated culture substrate, and the step (4) may be repeated. The repetition may be performed a plurality of times (eg, 2, 3, 4, 5, 6, 7, 8, 9 times).
  • Steps (1) to (4) a cell population containing high-purity hepatic progenitor cells from which fibroblasts have been removed can be produced, but the purity is further increased. Therefore, a further step may be performed.
  • the cells recovered in step (3) are cultured on a gelatin-coated culture medium, and the cells not adhered to the culture medium are cultured.
  • the process of collecting the culture medium can be mentioned.
  • the gelatin-coated culture medium used in the above step (3') is not particularly limited as long as the surface of the culture medium is coated with gelatin.
  • a prepared one may be used, or a commercially available product may be used.
  • For the gelatin-coated culture substrate for example, add an autoclaved 0.1% gelatin solution to the culture substrate, shake the culture substrate to spread the gelatin solution throughout, allow it to stand at room temperature for 10 minutes or more, and then add excess. It can be prepared by removing the gelatin solution.
  • Examples of commercially available products include gelatin-coated dishes (IWAKI) and bioCoat gelatin culture dishes (Corning International Co., Ltd.).
  • the cells recovered in step (3) were gelatin-coated with a cell density of, for example, 5 ⁇ 10 3 to 2 ⁇ 10 6 cells / cm 2 , preferably 5 ⁇ 10 4 to 5 ⁇ 10 5 cells / cm 2 . It can be seeded and cultured on a culture substrate.
  • the medium and culture conditions are the same as in step (4).
  • the culture time is not particularly limited as long as the cells adhere to the culture substrate, and is, for example, 10 minutes to 5 hours, preferably 20 minutes to 4 hours, and more preferably 30 minutes to 3 hours.
  • step (3') hepatic progenitor cells tend to be less likely to adhere to gelatin-coated culture substrates than fibroblasts. Therefore, the purity of hepatic progenitor cells can be increased by collecting unadhered cells after culturing.
  • Step (5) for example, after the step (4), the cells recovered in the step (4) are cultured on a collagen-coated culture substrate, and the cells not adhered to the culture substrate are removed.
  • Examples of the collagen-coated culture medium used in step (5) include the same as those used in step (4).
  • the cells recovered in step (4) can be seeded on a collagen-coated culture medium at a cell density half that of step (4), for example.
  • the medium and culture conditions are the same as in step (4).
  • the culture time is not particularly limited as long as the cells adhere to the culture substrate, and for example, the cells may be cultured until they reach confluence. Specific culture times include, for example, 90 to 3 days (eg, 90 days, 80 days, 70 days, 60 days, 50 days, 40 days, 35 days, 30 days, 28 days, 24 days, 21 days. , 18 days, 14 days, 12 days, 10 days, 7 days, 5 days, 4 days, 3 days).
  • step (5) there are more hepatic progenitor cells than fibroblasts, and as a result, more hepatic progenitor cells tend to adhere to the collagen-coated culture medium. Therefore, after culturing, the purity of hepatic progenitor cells can be increased.
  • step (3) the series of steps of step (3'), step (4) and step (5) is performed one or more times (eg, 2, 3, 4, 5, 6, 7, 8, 9 times). You may. Further, the series of steps of step (4) and step (5) may be performed one or more times (eg, 2, 3, 4, 5, 6, 7, 8, 9 times).
  • step (6) there is a step (step (6)) in which the cells adhered to the culture base material in the step (5) are separated from the culture base material and recovered before reaching the confluence.
  • "Before reaching confluence” refers to a state of 20-95% confluence, preferably 50-90% confluence, more preferably 70-85% confluence. Examples of the method for exfoliating the cells and the method for recovering the exfoliated cells include the same method as in step (3).
  • hepatic progenitor cells tend to exfoliate more easily by trypsin treatment than fibroblasts. Therefore, the purity of hepatic progenitor cells can be increased by recovering the cells exfoliated by trypsin treatment.
  • Step (7) the cells adhering to the culture substrate in the step (5) are separated from the culture substrate and recovered after reaching the confluence.
  • Step (7) may be performed.
  • “reached confluence” is meant 90-100% confluence, preferably 95-100% confluence, more preferably 98-100% confluence.
  • Examples of the method for exfoliating the cells include the same method as in step (3).
  • the method for collecting the detached cells is not particularly limited. For example, the dish is gently shaken before pipetting the cells to detach and remove the network-aggregated cells (eg, fibroblasts), and then the tip diameter. A method of collecting newly exfoliated cells after pipetting the cells with a large 5 mL pipette or the like can be mentioned.
  • hepatic progenitor cells tend to be more difficult to exfoliate due to trypsin treatment than fibroblasts. Therefore, the purity of hepatic progenitor cells can be increased by removing the cells exfoliated by trypsin treatment.
  • the present invention also provides a cell population containing hepatic progenitor cells (hereinafter, may be referred to as "cell population of the present invention") obtained by the production method of the present invention. To do.
  • the proportion of hepatic progenitor cells (number of hepatic progenitor cells / total number of cells) in the cell population is at least 50% or more, preferably 60% or more, more preferably 70% or more, still more preferably 80%. The above is most preferably 90% or more.
  • the proportion of hepatic progenitor cells is 90% or more (eg, 91, 92, 93, 94, 95, 96, 97, 98, 99 or A cell population containing the hepatic progenitor cells, which is 100%), is provided.
  • the proportion of hepatic progenitor cells can be measured by flow cytometry using the marker described in 1. above as an index.
  • Such a cell population may have a higher proportion of hepatic progenitor cells and a higher activity than the cell population obtained by the conventional method.
  • the present invention also provides a cell transplantation therapeutic agent (hereinafter, may be referred to as “cell transplantation therapeutic agent of the present invention”) containing the cell population of the present invention.
  • the cell population of the present invention is a high-quality cell population having the property of having high purity of hepatic progenitor cells. Therefore, the cell population of the present invention is suitable for use as a raw material for a cell transplantation therapy agent, and the cell population or the cell transplantation therapy agent of the present invention contains alcoholic or non-alcoholic liver injury, liver fibrosis, and the like. It is useful for the treatment, improvement or prevention of fatty liver and the like.
  • an effective amount of the cell population or cell transplant therapy agent of the present invention is administered or transplanted to a mammal (eg, human, mouse, rat, monkey, cow, horse, pig, dog, etc.) to be treated or prevented.
  • a mammal eg, human, mouse, rat, monkey, cow, horse, pig, dog, etc.
  • Treatment, amelioration or prevention of liver damage are also included in the present invention.
  • the liver disorder to be treated, improved or prevented is not particularly limited, and examples thereof include hepatitis such as viral hepatitis, acute hepatitis and chronic hepatitis, alcoholic liver disorder, drug-induced liver disorder and the like.
  • the cell population of the present invention When used as a cell transplant therapy agent, it contains hepatic progenitor cells established from stem cells having the same or substantially the same HLA genotype of the transplanted individual from the viewpoint of not causing rejection. It is desirable to use a cell population.
  • substantially the same means that the transplanted cells have the same HLA genotype to the extent that the immunosuppressant can suppress the immune response.
  • HLA-A and HLA-B It is a somatic cell having an HLA type in which 3 loci of HLA-DR or 4 loci with HLA-C are matched.
  • the mutation in the gene is repaired in advance by using a technique such as genome editing (eg, CRISPR system, TALEN, ZFN, etc.). Is preferable. If sufficient cells cannot be obtained due to age or constitution, it is possible to implant them in capsules such as polyethylene glycol or silicon, or in a porous container to avoid rejection. is there.
  • genome editing eg, CRISPR system, TALEN, ZFN, etc.
  • the cell population is produced as a parenteral preparation such as an injection, a suspension, or an infusion by mixing with a pharmaceutically acceptable carrier according to conventional means.
  • Pharmaceutically acceptable carriers that may be included in the parenteral preparation include, for example, isotonic solutions containing saline, glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.). Can be mentioned as an aqueous solution for injection.
  • the cell transplantation therapeutic agent of the present invention is, for example, a buffer (for example, phosphate buffer, sodium acetate buffer), a pain-relieving agent (for example, benzalkonium chloride, prokine hydrochloride, etc.), a stabilizer (for example, human).
  • the transplant therapeutic agent of the present invention may be formulated as an aqueous suspension
  • the cell population may be suspended in the aqueous solution so as to have a concentration of about 1 ⁇ 10 6 to about 1 ⁇ 10 8 cells / mL.
  • the dose or transplantation amount and the number of administrations or the number of transplants of the cell population or the cell transplant therapy agent of the present invention can be appropriately determined depending on the age, body weight, symptoms and the like of the mammal to be administered.
  • the cell transplantation therapy agent of the present invention is provided in a cryopreserved state under conditions normally used for cryopreservation of cells (eg, CELLBANKER® 1 (Takara Bio Inc.)), and is thawed before use. It can also be used.
  • serum or a substitute thereof an organic solvent (eg DMSO) and the like may be further contained.
  • the concentration of serum or a substitute thereof is not particularly limited, but may be about 1 to about 30% (v / v), preferably about 5 to about 20% (v / v).
  • the concentration of the organic solvent is not particularly limited, but may be 0 to about 50% (v / v), preferably about 5 to about 20% (v / v).
  • the present invention also provides a cell population containing hepatocytes or bile duct epithelial cells obtained by inducing differentiation of the cell population of the present invention.
  • Induction of differentiation of hepatic progenitor cells into hepatocytes can be performed by a method known per se. For example, a method of culturing in a culture medium containing oncostatin M (OsM), dexamethasone (Dex), hepatocyte growth factor (HGF), etc.
  • OsM oncostatin M
  • Dex dexamethasone
  • HGF hepatocyte growth factor
  • a TGF ⁇ receptor inhibitor, a GSK3 inhibitor, and a ROCK inhibitor may or may not be added to the medium for inducing differentiation into hepatocytes, but it is preferable to add them.
  • Induction of differentiation of hepatic progenitor cells into BEC can be performed by a method known per se. For example, a method of culturing in a medium containing EGF and insulin-like growth factor 2 (IGF2) using a collagen gel can be mentioned. Alternatively, the method described in WO2017 / 119512 may be used.
  • the present invention also comprises contacting the hepatocytes or bile duct epithelial cells of the present invention with the test compound, and the metabolism of the test compound in the mammalian body.
  • a method for evaluating hepatotoxicity of a test compound to a mammal is provided. These methods include a step of measuring the metabolism of the test compound in hepatocytes, or a step of detecting or measuring the presence or absence of damage to the cells or the degree thereof.
  • test compound used in the present invention is not particularly limited.
  • single compounds such as foreign substances, natural compounds, organic compounds, inorganic compounds, proteins, peptides, as well as compound libraries, expression products of gene libraries, cell extracts, cell culture supernatants, fermented microbial products, etc.
  • Examples include, but are not limited to, marine organism extracts, plant extracts, and the like.
  • Examples of the foreign body include, but are not limited to, candidate compounds for drugs and foods, and existing drugs and foods, and are included in the foreign bodies of the present invention as long as they are foreign substances to the living body.
  • Rifampin Dexamethasone, Phenobarbital, Ciglirazone, Phenytoin, Efavirenz, Simvastatin, ⁇ -Naphthoflavone, Omeprazole, Clotrimazole, 3-Methylcholanthrene and the like can be exemplified.
  • Contact between hepatocytes and the test compound is usually performed by adding the test compound to the medium or culture medium, but the method is not limited to this method.
  • the test compound is a protein or the like, contact can be made by introducing a DNA vector expressing the protein into the cell.
  • the metabolism of the test compound can be measured by a method well known to those skilled in the art. For example, when a metabolite of a test compound is detected, it is determined that the test compound has been metabolized. In addition, when the expression of enzyme genes such as CYP (cytochrome p450), MDR, and MRP is induced by contact with the test compound, or when the activity of these enzymes is increased, it is determined that the test compound is metabolized. To. In addition, the degree of damage can be measured using, for example, the survival rate of hepatocytes or liver damage markers such as GOT and GPT as indicators.
  • Example 1 Preparation of cell population including hepatic progenitor cells and fibroblasts (step (1)) 1-1. Preparation of primary human hepatocytes 1-1-1. Reagent
  • total volume 50 mL was dispensed into two conical tubes of 25 mL each and centrifuged. (9) The supernatant was discarded, and a certain amount (20 to 30 mL) of Hep 1 medium was added to the remaining pellets. Cell count and viability were measured.
  • hCLiP human Chemically-induced Liver Progenitors
  • SHM + YAC medium preparation
  • SHM human Chemically-induced Liver Progenitors
  • SHM + YAC a small hepatocyte culture medium
  • CLiP hepatic progenitor cells derived from mature hepatocytes by Y-27632, A-83-01, and CHIR99021 (YAC).
  • Hepatocytes were obtained from hepatocytes by a reprogramming method using a low molecular weight compound. Specifically, it is as follows.
  • the human primary hepatocytes obtained in the above "1-1. Preparation of human primary hepatocytes" were seeded (SHM + YAC) on a collagen-coated dish at 1.2 ⁇ 10 4 cells / cm 2 .
  • the medium was changed once every two days, and the cells were cultured at 37 ° C. (for 1 to 2 months) until they became confluent. Processed for 10 minutes with TrypLE TM Express and passed. (By combining the following fibroblast removal methods, high-purity hCLiP can be obtained around Passege 1-3.)
  • step (2) and step (3) Under a microscope, the positions of fibroblast colonies (appearing from about the 10th day of culture) were marked on the culture substrate with oil-based magic. Fibroblast colonies were physically exfoliated using a scraper, pipette tip, or the like. The supernatant (exfoliated fibroblasts) was removed by washing twice in the culture medium. It was done a couple of times before becoming confluent. Processed for 10 minutes with TrypLE TM Express and passed. The step of physically removing the fibroblast colonies from the cell substrate was performed as shown in the upper part of FIG.
  • the collected cells are cultured on a gelatin-coated culture medium, and the cells that have not adhered to the culture medium are collected (step (3')).
  • the passaged hCLiP were seeded in gelatin-coated dishes (IWAKI) to 2.5 ⁇ 10 5 cells / cm 2 (SHM + YAC), and cultured at 37 ° C. 30 minutes to adhere the cells (Gelatin), 2 in the culture medium The supernatant (unattached cells) was collected by washing once.
  • the collected cells are cultured on a collagen-coated culture medium, and the cells that have not adhered to the culture medium are collected (step (4)).
  • the collected unadhered cells are seeded on a collagen-coated dish (IWAKI) at 5.0 ⁇ 10 4 cells / cm 2 (SHM + YAC), cultured at 37 ° C for 10 minutes to adhere the cells (Collagen 1), and cultured medium.
  • the supernatant (unattached cells) was collected by washing twice with.
  • step (5) Cultivate the recovered cells on a collagen-coated culture medium and remove cells that have not adhered to the culture medium (step (5)).
  • the collected unadhered cells are seeded (SHM + YAC) on a collagen-coated dish (IWAKI) at 2.5 ⁇ 10 4 cells / cm 2 , and the cells are adhered at 37 ° C., the unattached cells are removed, and confluence is reached. Incubated to (Collagen 2).
  • Results are shown in Figure 2.
  • the left is a phase-contrast microscope image of cells cultured for 1 day on a gelatin-coated culture medium in 3. above. Only fibroblasts were adhered, and hCLiP was hardly detected.
  • the center is a phase-contrast microscope image of cells cultured for 12 days on a collagen-coated culture medium in 4. above. Many fibroblasts proliferated, and hCLiP was partially observed.
  • the right is a phase-contrast microscope image of cells cultured for 12 days on a collagen-coated culture medium in 5. above. Most were hCLiP and few fibroblasts. Visually confirmed, the hCLiP / total cell count ratio was at least 80% or higher.
  • Example 2 Cells adhered to a collagen-coated culture medium were obtained by the same method as in Examples 1 to 5. The cells were collected, and 3 to 5 of Example 1. The same operation as in the above was carried out to obtain cells adhered to a collagen-coated culture medium. The cells were collected, and the same operations as in 3 and 4 of Example 1 were performed. It was confirmed that the cells cultured in 4 became confluent, and the same enzyme treatment as in Example 1 was performed. The cells were detached and collected. Subsequently, the collected cells were subjected to the same operations as in steps 3 to 5 of Example 1. In the operation of 5, the culture period until reaching confluence was 28 days.
  • the method of the present invention can sufficiently remove fibroblasts from a cell population containing hepatocyte-derived hepatic progenitor cells and fibroblasts, and thus fibroblasts are sufficiently removed from the hepatic progenitor cells. It can be used to produce increased purity cell populations.

Abstract

La présente invention concerne un procédé de préparation d'une population cellulaire comprenant des cellules précurseurs du foie, le procédé comprenant (1) une étape de préparation d'une base de culture qui comprend une population cellulaire comprenant des cellules précurseurs du foie et des fibroblastes, (2) une étape d'élimination physique de la colonie de fibroblastes à partir de la base de culture, (3) une étape d'élimination des cellules à partir de la base de culture et de collecte des cellules éliminées, et (4) une étape de culture des cellules collectées à l'étape (3) dans une base de culture revêtue de collagène et de collecte des cellules qui n'ont pas adhéré à la base de culture.
PCT/JP2020/013987 2019-03-29 2020-03-27 Procédé de préparation d'une population cellulaire comprenant des cellules précurseurs du foie WO2020203753A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/599,619 US20220160785A1 (en) 2019-03-29 2020-03-27 Method for manufacturing cell population including liver precursor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068911A JP7284985B2 (ja) 2019-03-29 2019-03-29 肝前駆細胞を含む細胞集団を製造する方法
JP2019-068911 2019-03-29

Publications (1)

Publication Number Publication Date
WO2020203753A1 true WO2020203753A1 (fr) 2020-10-08

Family

ID=72669111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/013987 WO2020203753A1 (fr) 2019-03-29 2020-03-27 Procédé de préparation d'une population cellulaire comprenant des cellules précurseurs du foie

Country Status (3)

Country Link
US (1) US20220160785A1 (fr)
JP (1) JP7284985B2 (fr)
WO (1) WO2020203753A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022188788A1 (fr) * 2021-03-08 2022-09-15 上海赛立维生物科技有限公司 Préparation de régulation et de contrôle d'une maladie hépatique et application correspondante

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520474A (ja) * 2005-12-21 2009-05-28 ユニヴァルシテ カソリック デ ルーバン 単離肝幹細胞
JP2011514169A (ja) * 2008-03-17 2011-05-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 幹細胞培養のためのマイクロキャリア
WO2013018851A1 (fr) * 2011-08-02 2013-02-07 独立行政法人国立がん研究センター Procédé d'induction de la différentiation hépatique à partir d'une cellule souche hépatique induite et d'une cellule progénitrice hépatique induite
WO2017119512A1 (fr) * 2016-01-08 2017-07-13 国立研究開発法人国立がん研究センター Procédé de production de cellules souches/précurseurs hépatiques à partir de cellules hépatiques matures à l'aide d'un composé de faible poids moléculaire
WO2018079714A1 (fr) * 2016-10-28 2018-05-03 国立研究開発法人国立がん研究センター Procédé de préparation de cellules progénitrices d'hépatocytes humains

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520474A (ja) * 2005-12-21 2009-05-28 ユニヴァルシテ カソリック デ ルーバン 単離肝幹細胞
JP2011514169A (ja) * 2008-03-17 2011-05-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 幹細胞培養のためのマイクロキャリア
WO2013018851A1 (fr) * 2011-08-02 2013-02-07 独立行政法人国立がん研究センター Procédé d'induction de la différentiation hépatique à partir d'une cellule souche hépatique induite et d'une cellule progénitrice hépatique induite
WO2017119512A1 (fr) * 2016-01-08 2017-07-13 国立研究開発法人国立がん研究センター Procédé de production de cellules souches/précurseurs hépatiques à partir de cellules hépatiques matures à l'aide d'un composé de faible poids moléculaire
WO2018079714A1 (fr) * 2016-10-28 2018-05-03 国立研究開発法人国立がん研究センター Procédé de préparation de cellules progénitrices d'hépatocytes humains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATSUDA, TAKESHI ET AL.: "Conversion of terminally committed hepatocytes to culturable biopotent progenitor cells with regenerative capacity", CELL STEM CELL, vol. 20, 2017, pages 41 - 55, XP055397277, DOI: 10.1016/j.stem.2016.10.007 *
MIYAJIMA, ATSUSHI ET AL.: "Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming", CELL STEM CELL, vol. 14, 2014, pages 561 - 574, XP055397279, DOI: 10.1016/j.stem.2014.04.010 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022188788A1 (fr) * 2021-03-08 2022-09-15 上海赛立维生物科技有限公司 Préparation de régulation et de contrôle d'une maladie hépatique et application correspondante
CN115094020A (zh) * 2021-03-08 2022-09-23 上海赛立维生物科技有限公司 抗肝纤维化制剂及其制备方法和应用

Also Published As

Publication number Publication date
US20220160785A1 (en) 2022-05-26
JP7284985B2 (ja) 2023-06-01
JP2020162551A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
US11795436B2 (en) Derivation of hepatic stem cells and mature liver cell types and uses thereof
US9931360B2 (en) Isolated liver stem cells
AU2015308341B2 (en) Method for producing adult liver progenitor cells
EP3250678A1 (fr) Procédés pour générer des constructions de tissu épithélial gastro-intestinal
US10961507B2 (en) Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound
JP6812003B2 (ja) 肝細胞及び肝非実質細胞、並びにそれらの調製方法
CA3013427A1 (fr) Preparations ameliorees de cellules progenitrices hepatiques adultes
US20220233605A1 (en) Methods of making and using liver cells
TWI448554B (zh) 肝星形細胞前驅體及其分離方法
WO2020080550A1 (fr) Procédé de production de cellules souches/précurseurs, à l'aide d'un composé de faible poids moléculaire, à partir de cellules dérivées de tissu ou d'organe endodermique
US20220282219A1 (en) Genetically engineered human fetal liver niche as platform for biomanufacturing of hematopoietic stem cells
WO2020203753A1 (fr) Procédé de préparation d'une population cellulaire comprenant des cellules précurseurs du foie
Raju et al. The road to regenerative liver therapies: the triumphs, trials and tribulations
KR102218549B1 (ko) 인간 타액선 세포의 배양 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20781978

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20781978

Country of ref document: EP

Kind code of ref document: A1